文献速递泌尿生殖技术与安全PETCT

[18F]Fluciclovine PET/CT 在评估非转移性去势抵抗性前列腺癌患者中的效用:诊断性能及对治疗管理的影响

The utility of [18F]Fluciclovine PET/CT in Evaluating Nonmetastatic Castrate-Resistant Prostate Cancer Patients (nmCRPCp): diagnostic performance and impact on management.
PubMed 文献 · Br J Radiol · 2023-10-24

本研究回顾性纳入35例非转移性去势抵抗性前列腺癌患者,因怀疑疾病进展行[18F]Fluciclovine PET/CT再分期。73%(26/35)扫描检出至少一处病灶,71%(25/35)患者治疗管理发生改变。以组织诊断和/或6个月临床影像随访为参考标准,诊断复发的敏感度86%、特异度83%、PPV 96.1%、NPV 55.5%。

要点

  • [18F]Fluciclovine PET/CT在nmCRPC患者中检出病灶率73%(26/35),管理改变率71%(25/35)。
  • 诊断复发敏感度86%、特异度83%、PPV 96.1%、NPV 55.5%,PPV高而NPV较低。
  • 26.9%(7/26)阳性患者为寡转移性疾病,Gleason评分与PET/CT阳性无关系。

核心结论

  • [18F]Fluciclovine PET/CT在常规影像失败的nmCRPC患者再分期中具有高PPV、敏感度和特异度,可检出软组织转移且不受初始Gleason评分影响,并常导致治疗管理改变。

研究设计与样本

  • 回顾性研究,纳入35例因怀疑疾病进展行[18F]Fluciclovine PET/CT再分期的非转移性去势抵抗性前列腺癌患者;两名放射科医生独立阅片、共识报告病灶部位和数量;以可获得组织诊断和/或6个月临床影像随访为参考标准。

关键影像表现/征象

  • 73%(26/35)的扫描中至少检出一处放射性示踪剂活性病灶。
  • 26.9%(7/26)阳性患者为寡转移性疾病。
  • Gleason评分与PET/CT阳性无关系。

诊断标准与关键数值

  • 以组织诊断和/或6个月临床影像随访为参考标准,[18F]Fluciclovine PET/CT检出nmCRPC复发的敏感度86%、特异度83%、PPV 96.1%、NPV 55.5%。

临床应用与阅片要点

  • 作者认为,鉴于高PPV、敏感度和特异度,[18F]Fluciclovine PET/CT可替代常规影像作为一线选择,因其优于骨扫描并可检出软组织转移,且不受初始Gleason评分影响。
  • 71%(25/35)患者治疗管理发生改变(22例阳性扫描和3例阴性扫描)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the role of [18F]Fluciclovine PET/CT scan in restaging nmCRPCp and its impact on management.

METHODS AND MATERIALS: This retrospective study included all patients with nonmetastatic castrate-resistant prostate cancer, who underwent [18F]Fluciclovine PET/CT scans for restaging who had concern for disease progression. Two radiologists independently reviewed the PET/CT studies, assigned an overall impression, and reported the site and number of radiotracer activities in consensus and impact on management was recorded. Available tissue diagnosis and/or six-month clinical and imaging follow-up were used as reference standards.

RESULTS: Thirty-five patients were included in this study. At least one lesion was detected in 73% (26/35) of the scans. Management changed in 71% (25/35) of patients, (22 positives and three negative scans). 26.9% (7/26) of patients were found to have an oligometastatic disease. Based on the reference standards, the diagnostic performance of [18F]Fluciclovine PET/CT in detecting recurrence in nmCRCP has 86%, sensitivity, 83% specificity, 96.1% PPV, and 55.5% NPV. There was no relationship between the Gleason score and a positive PET/CT scan in our patient population.

CONCLUSION: Detecting the source of recurrence is challenging in nmCRCP patients when conventional imaging fails. Given the high PPV, sensitivity, and specificity, [18F]Fluciclovine PET/CT can be used instead of conventional imaging as a first-line choice due to its superiority over bone scan and added value of detecting soft tissue metastasis regardless of the initial Gleason score.

ADVANCES IN KNOWLEDGE: The study highlights the added value of [18F]Fluciclovine PET/CT in detecting soft tissue metastasis regardless of the initial Gleason score, which is not possible with conventional imaging such as bone scans.The study highlights the potential role of [18F]Fluciclovine PET/CT guiding management change for nonmetastatic castrate-resistant prostate cancer patients, particularly those with oligometastatic disease.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Soliman M, Elfatairy K, Ellessy R, et al. The utility of [18F]Fluciclovine PET/CT in Evaluating Nonmetastatic Castrate-Resistant Prostate Cancer Patients (nmCRPCp): diagnostic performance and impact on management. Br J Radiol. 2023. PMID: 37750841. doi:10.1259/bjr.20230414

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。